Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 8Sarcoma 4Lymphoid 2Other hematologic neoplasm 1NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 13Pheochromocytoma 6Carcinoma, Neuroendocrine 6Somatostatinoma 5Paraganglioma 4Pituitary Neoplasms 3Insulinoma 3Glucagonoma 3Gastrinoma 3Zollinger-Ellison Syndrome 2Vipoma 2Paraganglioma, Extra-Adrenal 2Pancreatic Neoplasms 2Gastro-enteropancreatic neuroendocrine tumor 2Carcinoma, Medullary 2Carcinoma, Islet Cell 2Carcinoid Tumor 2Spinal Cord Neoplasms 1Small Cell Lung Carcinoma 1Rhabdoid Tumor 1Prolactinoma 1Optic Nerve Glioma 1Oligodendroglioma 1Non functioning pancreatic endocrine tumor 1Neuroectodermal Tumors, Primitive 1Neoplasms 1Neoplasm Metastasis 1Multiple Endocrine Neoplasia Type 2b 1Multiple Endocrine Neoplasia Type 2a 1Multiple Endocrine Neoplasia Type 1 1

Interventions

Everolimus 2trifluridine tipiracil drug combination 1surufatinib 1pegfilgrastim 1pasireotide 1gallium Ga 68 dotatate 1fosbretabulin 1entinostat 1dactolisib 1belzutifan 1Temozolomide 1TH 302 1Surveys and Questionnaires 1Sunitinib 1Photochemotherapy 1Nivolumab 1Filgrastim 1Fentanyl 1Dihematoporphyrin Ether 190Y-octreotide, DOTA-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroectodermal Tumors, Primitive × Temozolomide × Endocrine × Clear all
NCT02943733 2022-09-23

Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs

University of Wisconsin, Madison

Phase 1 Terminated
18 enrolled
EndocrineNET

Neoplasms, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡